MC16
Amyotrophic Lateral Sclerosis (ALS)
Key Facts
About MitoChem Therapeutics
MitoChem Therapeutics is a preclinical-stage biotech targeting neurodegenerative diseases by addressing their root metabolic cause: mitochondrial dysfunction. The company's core platform is a library of mitochondrial-protective small molecules, with lead candidate MC16 designed to correct the mislocalization of the RNA-binding protein FUS, thereby restoring cellular energy balance. Its initial focus is on Amyotrophic Lateral Sclerosis (ALS) and Retinitis Pigmentosa (RP), aiming to provide mutation-agnostic therapies for these high-need indications. As a private, pre-revenue company, MitoChem is advancing its programs through preclinical proof-of-concept studies.
View full company profileAbout MitoChem Therapeutics
MitoChem Therapeutics is a preclinical-stage biotech targeting neurodegenerative diseases by addressing their root metabolic cause: mitochondrial dysfunction. The company's core platform is a library of mitochondrial-protective small molecules, with lead candidate MC16 designed to correct the mislocalization of the RNA-binding protein FUS, thereby restoring cellular energy balance. Its initial focus is on Amyotrophic Lateral Sclerosis (ALS) and Retinitis Pigmentosa (RP), aiming to provide mutation-agnostic therapies for these high-need indications. As a private, pre-revenue company, MitoChem is advancing its programs through preclinical proof-of-concept studies.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis (ALS) Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT520-34 | Neuropore Therapies | Pre-clinical/Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Phase 2/3 (Platform Trial) |
| CNM-Au8 | Clene | Phase 2/3 |
| Masitinib | AB Science | Phase 3 |
| Undisclosed Program | Zhimeng Biopharma | Clinical |
| SLS-005 | Seelos Therapeutics | Platform Trial |
| PMN442 | ProMIS Neurosciences | Preclinical |
| nAV-101 | nVector | Pre-clinical |
| ALTA-808 | Alteron Therapeutics | Preclinical |
| GM6 | Genervon Biopharmaceuticals | Phase 2 |
| Lou Gehrig’s disease | Genclis | Discovery |
| Treg-directed therapy for ALS | Iltoo Pharma | Pre-clinical |